companydirectorylist.com  Global Business Directories and Company Directories
Search Business,Company,Industry :


Country Lists
USA Company Directories
Canada Business Lists
Australia Business Directories
France Company Lists
Italy Company Lists
Spain Company Directories
Switzerland Business Lists
Austria Company Directories
Belgium Business Directories
Hong Kong Company Lists
China Business Lists
Taiwan Company Lists
United Arab Emirates Company Directories


Industry Catalogs
USA Industry Directories














  • R D Antibody Discovery Partner | Fusion Antibodies
    Fusion Antibodies offer a complete end-to-end service from antigen design to cell line development R D Antibody Discovery Partner
  • About Us - Fusion Antibodies
    Fusion Antibodies are world leaders with over 20 years experience in antibody development services specializing in the discovery, engineering and supply of pre-clinical biologics through to clinical Cell Line Development
  • Antibody Discovery | Fusion Antibodies
    Antibody Discovery projects are built with a range of antigen design options, immunisation scheduling, host species and screening strategies
  • Contact Us - Fusion Antibodies
    Contact us about Antibody Humanization Optimize your antibody to be the best Contact us to start a project
  • Fusion Antibodies News
    Fusion Antibodies, pre-clinical antibody discovery and development experts and BioTickle, their exclusive distributor in India, are providing local biopharmaceutical organisations with access to invaluable unique biopharmaceutical development capabilities
  • LSE:FAB - Deep Dive: The Opti Library
    In this episode, Chief Scientific Officer Richard Buick unpacks the science and significance of Fusion’s Opti Library, a cornerstone of their antibody discovery toolkit Richard explains what makes the Opti Library unique: a highly diverse, carefully curated collection of antibody sequences designed to accelerate the identification of promising therapeutic candidates He highlights how the
  • LSE:FAB - Company Update Presentation - May 2025
    In the latest investor presentation CEO Dr Adrian Kinkaid and interim CFO Stephen Smyth provided a comprehensive overview of Fusion Antibodies performance and strategic direction for the financial year ended 31 March 2025 Key highlights include:Strong Revenue Growth: Unaudited annual revenues rose by 71% to £1 96 million driven by robust performance across both discovery and diagnostic
  • Home | Fusion Antibodies plc investor hub
    View share price, top shareholders, your shareholding, and interact with announcements for Fusion Antibodies plc




Business Directories,Company Directories
Business Directories,Company Directories copyright ©2005-2012 
disclaimer